Jump to main content
Topic: Policy
-
Biosimilars in Medicare Part D: pricing dynamics and considerations
Read More
-
Evaluating Industry’s Drug Pricing Claims
Read More
-
Value-Based Management of Specialty Drugs: Practical Considerations and Implications for Pharmacy
Read More
-
Trump’s Drug-Pricing Ideas Would Cost Taxpayers a Bundle
Read More
-
After 4 Years of Trump, Medicare and Medicaid Badly Need Attention
Read More
-
CMS’s Proposed Medicaid Best Price Loophole for Value-Based Purchasing of Drugs
Read More
-
The Drugs at the Heart of Our Pricing Crisis
Read More
-
Biosimilars: Market Changes do not equal policy success
Read More
-
Bottom-Up Pricing Estimate for P-quad
Read More
-
Modeling P-quad
Read More